Risk Of Developing Liver Cancer After HCV Treatment

▼

Wednesday, April 11, 2018

HCC Trials Spur Treatment Landscape Forward

HCC Trials Spur Treatment Landscape Forward
Caroline Seymour
Published: Wednesday, Apr 11, 2018
Clinical trials continue to investigate the use of immunotherapy agents in advanced hepatocellular carcinoma (HCC), especially with the phase III CheckMate-459 trial in which nivolumab (Opdivo) is being compared with sorafenib (Nexavar) in the frontline setting.

“CheckMate-459 has completed accrual and will likely be the next big story in HCC because it has the potential to change not only the standard of care, but the entire treatment landscape,” says R. Kate Kelley, MD.
at

No comments:

Post a Comment